HomeCompareSGCPF vs JNJ

SGCPF vs JNJ: Dividend Comparison 2026

SGCPF yields 3992.02% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SGCPF wins by $7038408636820.30M in total portfolio value
10 years
SGCPF
SGCPF
● Live price
3992.02%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7038408636820.33M
Annual income
$6,707,864,260,492,553,000.00
Full SGCPF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SGCPF vs JNJ

📍 SGCPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGCPFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGCPF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGCPF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGCPF
Annual income on $10K today (after 15% tax)
$339,321.36/yr
After 10yr DRIP, annual income (after tax)
$5,701,684,621,418,670,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, SGCPF beats the other by $5,701,684,621,418,666,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGCPF + JNJ for your $10,000?

SGCPF: 50%JNJ: 50%
100% JNJ50/50100% SGCPF
Portfolio after 10yr
$3519204318410.18M
Annual income
$3,353,932,130,246,279,000.00/yr
Blended yield
95.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SGCPF
No analyst data
Altman Z
10.6
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGCPF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGCPFJNJ
Forward yield3992.02%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$7038408636820.33M$30.3K
Annual income after 10y$6,707,864,260,492,553,000.00$4,689.40
Total dividends collected$7015858891478.01M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SGCPF vs JNJ ($10,000, DRIP)

YearSGCPF PortfolioSGCPF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$409,902$399,201.60$10,592$272.30+$399.3KSGCPF
2$15,731,433$15,292,838.50$11,289$357.73+$15.72MSGCPF
3$565,353,313$548,520,679.36$12,123$472.89+$565.34MSGCPF
4$19,027,950,361$18,423,022,315.76$13,141$629.86+$19027.94MSGCPF
5$599,854,207,291$579,494,300,405.11$14,408$846.81+$599854.19MSGCPF
6$17,715,207,654,637$17,073,363,652,836.21$16,021$1,151.60+$17715207.64MSGCPF
7$490,188,440,412,516$471,233,168,222,053.44$18,122$1,588.22+$490188440.39MSGCPF
8$12,710,718,187,796,452$12,186,216,556,555,060.00$20,930$2,228.20+$12710718187.78MSGCPF
9$308,919,977,876,429,600$295,319,509,415,487,360.00$24,792$3,191.91+$308919977876.40MSGCPF
10$7,038,408,636,820,333,000$6,707,864,260,492,553,000.00$30,274$4,689.40+$7038408636820.30MSGCPF

SGCPF vs JNJ: Complete Analysis 2026

SGCPFStock

Solstice Gold Corp. engages in the exploration for and development of mineral resource properties in Ontario and Nunavut, Canada. It primarily explores for gold deposits. The company holds a 100% interest in the Kahuna gold project covering an area of 866 square kilometers located in Nunavut, as well as secondary rights covering an adjacent 683 square kilometres. It also has an option agreement to acquire a 100% interest in the Red Lake Extension project consisting of 10 claims located in the northern part of the Red Lake Gold District. The company was formerly known as Dunnedin Gold Inc. and changed its name to Solstice Gold Corp. in September 2017. Solstice Gold Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Full SGCPF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SGCPF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGCPF vs SCHDSGCPF vs JEPISGCPF vs OSGCPF vs KOSGCPF vs MAINSGCPF vs ABBVSGCPF vs MRKSGCPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.